Equities analysts predict that K2M Group Holdings Inc (NASDAQ:KTWO) will post ($0.18) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for K2M Group’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.20). K2M Group posted earnings of ($0.30) per share in the same quarter last year, which indicates a positive year over year growth rate of 40%. The business is scheduled to report its next quarterly earnings results on Monday, March 5th.

According to Zacks, analysts expect that K2M Group will report full-year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.88) to ($0.76). For the next year, analysts forecast that the firm will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.78) to ($0.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow K2M Group.

K2M Group (NASDAQ:KTWO) last released its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. During the same quarter in the previous year, the company posted ($0.19) EPS. The company’s revenue was up 5.6% compared to the same quarter last year.

A number of research firms recently issued reports on KTWO. Zacks Investment Research upgraded K2M Group from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Wednesday, October 4th. Needham & Company LLC dropped their price target on K2M Group from $27.00 to $26.00 and set a “strong-buy” rating on the stock in a research note on Thursday, November 2nd. Wells Fargo & Co dropped their price target on K2M Group from $28.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 10th. Oppenheimer restated a “buy” rating and set a $24.00 price target on shares of K2M Group in a research note on Friday, November 10th. Finally, Cowen restated an “outperform” rating and set a $22.00 price target (down previously from $28.00) on shares of K2M Group in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $24.40.

Institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA lifted its position in K2M Group by 5,175.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock worth $109,000 after acquiring an additional 4,399 shares during the period. Cubist Systematic Strategies LLC lifted its position in K2M Group by 7,765.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock worth $100,000 after acquiring an additional 4,659 shares during the period. Rockefeller Financial Services Inc. acquired a new stake in K2M Group during the 3rd quarter worth approximately $105,000. Dorsey & Whitney Trust CO LLC acquired a new stake in K2M Group during the 2nd quarter worth approximately $211,000. Finally, Legal & General Group Plc lifted its position in K2M Group by 41.4% during the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock worth $232,000 after acquiring an additional 2,798 shares during the period. 97.95% of the stock is owned by institutional investors.

K2M Group (NASDAQ KTWO) traded up $0.89 on Thursday, hitting $19.19. The stock had a trading volume of 426,782 shares, compared to its average volume of 339,427. K2M Group has a fifty-two week low of $16.44 and a fifty-two week high of $25.99. The stock has a market cap of $831.47, a P/E ratio of -19.99 and a beta of 1.34. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 0.29.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/analysts-anticipate-k2m-group-holdings-inc-ktwo-will-announce-earnings-of-0-18-per-share-updated-updated-updated.html.

K2M Group Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.